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Abstract 
Silent cerebral infarction is the commonest neurological abnormality in children with 
sickle cell anemia, affecting 30-40% 14 year olds. There are no known biomarkers to 
identify children with silent cerebral infarcts and the pathological basis is also 
unknown. We used an unbiased proteomic discovery approach to identify plasma 
proteins differing in concentration between children with and without silent cerebral 
infarcts. Clinical parameters and plasma samples were analysed from 51 children 
(mean age 11.8 years, range 6-18) with sickle cell anemia (HbSS). 19 children had 
silent cerebral infarcts and 32 normal MRI; the children with silent infarcts had lower 
HbF levels (8.6 vs. 16.1%, P=0.049) and higher systolic blood pressures (115 vs 108.6, 
P=0.027). Plasma proteomic analysis showed 13 proteins increased more than 1.3 
fold in the SCI patients, including proteins involved in hypercoagulability (α2-
antiplasmin, fibrinogen−γ chain, thrombospondin-4), inflammation (α2-
macroglobulin, complement C1s and C3) and atherosclerosis (apolipoprotein B-100). 
Higher levels of gelsolin and retinol-binding protein 4 were also found in the 
population with silent infarcts, both of which have been linked to stroke. We 
investigated the genetic basis of these differences by studying 359 adults with sickle 
cell disease (199 with silent cerebral infarcts, 160 normal MRIs), who had previously 
undergone a genome-wide genotyping array. None of the genes coding for the 
differentially expressed proteins were significantly associated with silent infarction. 
Our study suggests that silent cerebral infarcts in sickle cell anemia may be 
associated with higher systolic blood pressure, lower HbF levels, hypercoagulability, 
inflammation and atherosclerotic lipoproteins.  
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Introduction 
Sickle cell anemia (SCA) is the commonest cause of stroke in childhood (1). The 
abnormal sickle hemoglobin (HbS) polymerizes when deoxygenated, damaging red 
cells, causing vaso-occlusion and vascular endothelial dysfunction (2). A cascade of 
pathological processes follows, including inflammation, hemolysis, anemia, oxidative 
stress, reperfusion injury, hypercoagulability, and nitric oxide deficiency (3). Survival 
is reduced by 20-30 years (4, 5) and vasculopathic complications include pulmonary 
hypertension, priapism, and cerebrovascular disease (6). The latter is the major 
cause of morbidity in children and takes two forms: overt stroke often associated 
with large vessel disease (7), and silent cerebral infarcts (SCI) of less certain 
pathology (8). Without intervention, overt stroke has a peak incidence of 1.02/100 
patient years between 2 and 5 years (9), although primary prevention using 
transcranial Doppler (TCD) scanning and blood transfusion reduces this by 90% (10). 
The implementation of TCD-based stroke prevention has led to a significant fall in 
overt strokes in many countries (11, 12). SCI is more common than overt stroke with 
MRI showing relevant lesions in 13% of two year olds, 25% of six year olds, and 30-
40% of 14 year olds(13).  
 
Although by definition SCIs are not associated with overt symptoms, they cause 
significant morbidity, including a reduction in IQ, defects in executive function, 
epilepsy, and increased risk of further SCIs and overt strokes (13). Early detection of 
SCI is useful to allow cognitive assessment, educational support and therapeutic 
intervention. The Silent Cerebral Infarct Multi-Center Clinical Trial (SIT Trial), a 
randomised controlled study, showed that regular blood transfusion reduced the 
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incidence of recurrent infarction in children with SCIs compared to the observational 
arm (14). 
 
The pathophysiology of SCI is unclear. It is often stated that SCIs are caused by small 
vessel disease, although there is no direct evidence for this. There are no post-
mortem studies looking at the histological changes corresponding to the MRI 
appearances of SCI, although older studies identified small necrotic lesions in the 
subcortex of the brain, possibly representing SCIs (15). It is also possible that SCIs are 
areas of demyelination, or linked to venous sinus thrombosis (13). SCIs may also be 
caused by difficulties maintaining constant blood flow to the brain, leading to 
watershed infarction precipitated by acute anemia or hypoxia(16). The lack of 
pathophysiological understanding makes it difficult to develop new therapeutic 
strategies. Here we used an unbiased proteomic approach to identify plasma 
proteins associated with SCI and potentially linked to the underlying 
pathophysiology. 
 
It is not easy to identify children with or at increased risk of SCI. Baseline data from 
the SIT Trial showed that steady state hemoglobin <7.6g/dl, steady state systolic 
blood pressure >104mmHg and male sex were all associated with increased risk of 
SCI, although a model combining all three significant factors had weak predictive 
powers, with a C statistic of about 0.6 (8). Abnormal transcranial Doppler velocities 
are not reliably associated with SCI, although there is a possible association with 
stenosis of the cervical internal carotid artery (17). Neuropsychometry can detect 
some children with SCIs, but is time consuming and not easily available. MRI is 
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currently the only way of diagnosing SCI, although before 7 years of age this usually 
requires sedation or general anesthetic, which carries significant risks in children 
with SCD and is unsuitable for screening. MRI is also not widely available in many 
African countries where SCA is most prevalent. It would therefore be beneficial to 
develop a simple, screening test for SCI, potentially based on blood testing. 
 
Proteomics can detect, identify and quantify very low concentrations of proteins. For 
example, a recent study suggested that urine proteomics might help in the diagnosis 
of acute stroke by detecting brain peptides released by ischemia (18). The presence 
of SCI may suggest small blood vessel disease and a tendency to infarct brain tissue, 
which is likely to be a chronic process, releasing detectable brain proteins into 
plasma. Plasma protein profiles could also differ between those with and without SCI 
because of causative pathological factors, including coagulopathy, inflammation, 
hypoxia and vasculopathy; these differences may be acquired or inherited, and 
reflect genetic predisposition to silent cerebral infarction. We investigated the 
possibility that there might be differences in the plasma proteome between children 
with and without SCIs, with a view to understanding more about the 
pathophysiology of SCIs and identifying potentially useful biomarkers. We further 
investigated the hypothesis that genetic factors account for the differences in 
concentrations of the various proteins, using data from a genome wide association 
study (GWAS) in a separate cohort of patients with SCA and SCIs. 
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Methods 
Patients and setting  
The National Research Ethics Committee approved the study (reference 
13/LO/0709). Children were recruited from clinics at King’s College Hospital and the 
Evelina Children’s Hospital. Approximately 1000 different children are seen annually 
in these clinics with a further 500 seen in outreach clinics (19). The aim was to recruit 
a total of 50 patients, with equal numbers of those with SCIs and controls with 
normal brain MRIs. Children known to have SCIs from previous MRI scans were 
selectively recruited. Eligible patients without previous MRIs were recruited 
sequentially in clinic, on the basis that 20-30% of these children would have SCIs, and 
combining the two groups would result in approximately 25 children in each group. 
SCI and control groups were not specificaly matched for age and gender. Inclusion 
criteria were: sickle cell anemia (HbSS), age 8-18 years old, normal or conditional 
TCD velocities (<200cm/s) (10), able to tolerate MRI scan without sedation. Exclusion 
criteria were: history of overt stroke, blood transfusion in last 4 months, serious co-
existing disorder (renal failure, HIV, hepatitis, malignancy, autoimmune disease, 
chronic infection, cardiac disease, long-term medication), acute complications 
requiring hospital attendance in last 3 months. Patients on hydroxyurea (HU) were 
recruited to both arms. Routine clinical and laboratory data were collected. 
 
Brain MRI and neurological assessment 
Brain MRIs were performed to identify the presence of SCIs using standardised 
definitions (20) (see Supplementary Materials). On the day of blood sampling, all 
children underwent standardised neurological examination by experienced clinicians 
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to document the absence of neurological abnormalities suggestive of an overt 
stroke. All children had routine TCD scans performed at least annually, and these 
were used in this study. 
 
Proteomic Analysis 
Blood samples were collected on all children at the time of consent. A data-driven 
proteomics approach was used to discover protein changes in the plasma associated 
with SCI. We used an established workflow combining isobaric Tandem Mass Tags 
(TMT) reagents with off gel fractionation, followed by high sensitivity rapid 
throughput mass spectrometry (MS) and LC-MS/MS. (details in Supplementary 
Materials). Relative amounts of each peptide were compared between the SCI and 
control groups, and P values were calculated for those peptides showing greater 
than 1.3 fold differences. 
 
Targeted plasma analysis for biomarkers of neurological disease 
Plasma samples were also analysed for 92 protein biomarkers known to be 
implicated in neurological disease, using a multiplexed proximity extension assay(21) 
(see Supplementary Materials for full list of biomarkers). 
 
Data Analysis 
Statistical significance was assessed using appropriate tests to compare means with 
adjustments for multiple comparisons when appropriate. Statistical analyses were 
performed in the proteomics laboratory and medical statistics department of Public 
Health Sciences at King’s College London. 
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Genetic association of protein biomarkers with SCIs 
The genes coding for plasma proteins which differed significantly between children 
with and without SCIs were identified using standard databases. Genetic association 
analysis was then undertaken in a separate adult cohort at KCH, evaluating the 
variants within each gene and their association with SCI (22) (details in 
Supplementary Materials). 
 
Results 
55 patients consented to take part in the study, although no blood samples were 
taken from one, and three further patients did not have an MRI scan performed. 
Plasma from 54 patients underwent proteomic analysis, although only data from the 
51 patients (22 female) with MRI results were analysed. 19 (37%) had SCIs and 32 
(63%) normal brain MRIs, deviating slightly from the aim of equal numbers in each 
groups because of recruitment of children without previous MRIs, the majority of 
whom had normal brain imaging (Figure 1). 15 children were identified as having 
SCIs from scans performed as part of this study, and four children were recruited as 
a result previous MRI scans showing SCIs; in these four children, there was a median 
delay of 20 months (range 9 – 40 months) between MRI scan and blood sampling for 
proteomic analysis. One child had conditional velocities and 50 normal velocities on 
TCD scanning.  
 
Basic clinical and laboratory data 
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Relatively more males (13/29, 44%) than females (6/22, 27%) were in the SCI group, 
although this was not significantly different (Chi square, P=0.199). There was no 
significant difference in HU use between the SCI and control groups: controls 11/32 
(36%) on HU, SCI 7/19 (37%) on HU (Chi square, P = 0.86). G6PD assays were 
available for 45 patients, and there was no association with SCI: G6PD deficiency was 
present in 3/29 (10%) controls and 2/16 (12%) with SCIs (Chi square, P=0.83). Basic 
laboratory and clinical characteristics are summarized in Table 1.  Mean HbF levels 
were significantly lower (6.1% versus 8.6%, P=0.049), and mean systolic blood 
pressures significantly higher (115 versus 108.6, P=0.027) in those with SCIs 
compared to controls. 
 
Plasma proteomic analysis 
A total of 4662 different peptides were identified, although only 1312 were present 
in all 51 patient samples, corresponding to 346 different proteins. 44 peptides from 
13 different proteins were present at more than 1.3 times the concentration in the 
SCI patients compared to controls (Table 2), whereas 41 peptides from 4 proteins 
were more than 1.3 higher in the control population (Table 3). Proteins differentially 
expressed in the SCI group included those implicated in coagulation, lipid and 
inflammatory pathways. 
 
Genetic association of identified biomarkers with SCI  
We explored the possibility that differences in concentrations of proteins (Tables 2 
and 3) between SCI and control populations were inherited, using a different sample 
of adult patients who had undergone brain MRI and a genome wide genotyping 
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array. Of 359 patients with brain MRIs and MEGAchip data, 199 had SCI and 160 did 
not. Regions of interest were analysed for the candidate genes identified in the 
proteomic study; the most significant genetic variant from each region is shown in 
Table 4. No genetic variant in the candidate genes was significantly associated with 
SCI after correcting for multiple testing. A variant in gelsolin was closest to achieving 
significance (P=0.00029, threshold for significance 0.00009). 
 
Targeted plasma analysis 
Concentrations of 92 known neurological biomarkers were measured in the plasma 
of 54 patients who consented to the study and gave blood samples. 51 patients had 
MRI scans available and were analysed. In order to control for the potential effect of 
hydroxyurea, a logistic regression model was fitted for each biomarker; the 
dependent variable was SCI status, and the biomarker and hydroxyurea were 
included as covariates in each model. Seven biomarkers were significantly associated 
with SCI, but after correction for multiple hypotheses none of these were significant 
(Table 5). Several biomarkers were strongly correlated with each other and a 
heatmap of the correlation matrix indicated a moderate level of redundancy 
between them. A principal component analysis found that approximately 90% of the 
variance could be attributed to the first 30 principal components. None of the 
principal components were found to be differentially expressed with respect to SCI 
status, either with or without controlling for HU status. 
 
Discussion
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Our study found that the presence of SCI in SCA is associated with higher systolic 
blood pressures, an association that was also found in the SIT trial (8). Blood 
pressure is relatively low in SCA (23), possibly related to chronic anemia and 
subsequent vasodilatation, and the levels found in our study, with a mean of 
115mmHg in the SCI group, would not be considered hypertensive. The exact way in 
which relative systolic hypertension is associated with SCI in children with SCA is 
unknown, although systolic hypertension is linked with other vascular complications 
in SCA (overt stroke (23), renal insufficiency (24), and high tricuspid jet velocity (24)). 
Systolic hypertension is also a risk factor for SCI in the non-sickle population (25). 
The association between relative systolic hypertension and SCI in SCA seems robust, 
and is biologically plausible, although there is currently no evidence on whether it is 
beneficial to lower blood pressure in children with SCA, and at what level such 
treatment should be considered. 
 
We also found that higher HbF levels were protective against SCI. Increased HbF 
levels lessen the severity of SCA, with a clear association with decreased pain and 
longer life expectancy (2), but a more complex association with cerebrovascular 
complications. In the SIT Trial, HbF was not associated with SCI in a logistic 
regression model (8) and analysis of data from the Cooperative Study of Sickle Cell 
Disease also showed no protective effect of higher HbF levels (26). Other studies 
have suggested that there may be neurological benefit to having higher HbF levels. 
In France, HbF levels were higher in children without SCIs compared to those with 
(16.5% vs. 13.1%, P=0.02) (27); a Dutch study found that although HbF did not 
protect against the occurrence of SCIs, higher levels were associated with a smaller 
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volume of white matter hyperintensities (28); a study on Brazilian patients showed 
protection against stroke was associated with genetic determinants of high HbF 
levels, particularly BCL11A alleles (29). It seems likely that the inherited ability to 
make more HbF offers some protection against neurological injury in SCA, although 
this may not always be reflected in the measured HbF percentage, particularly in 
small studies. 
 
The unbiased proteomic discovery part of this study identified 44 peptides from 17 
different proteins which were significantly up or down regulated compared to levels 
in the control population, without correction for multiplicity (Tables 2 and 3). Many 
of these proteins can be plausibly implicated in pathogenesis of SCI and fall in to 
three broad groups.  
 
Prothrombotic proteins 
Four proteins which were found at higher levels in the SCI patients are known to be 
prothrombotic. α
2
-antiplasmin is a serine protease inhibitor which inactivates 
plasmin and decreases the rate of fibrinolysis; high levels are associated with 
increased ischemic stroke in the non-sickle population (30). Similarly, α
2
-
macroglobulin has prothrombotic properties via the inactivation of plasmin, and 
elevated levels have been linked to stroke and white matter lesions in non-sickle 
patients(31). The fibrinogen γ chain was increased 1.33 in the SCI population, and is 
at the center of fibrin polymerization, interaction with platelets and regulation of 
factor XIII activity (32). Increased levels have been associated with vasculopathy, 
higher levels being increased in inflammation and also possibly inherited (33). 
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Fourthly, thrombospondin-4 was increased 1.32 fold with SCI. Thrombospondins 
mediate cellular adhesion to other cells and matrix, and are implicated in many 
thrombotic and vasculopathic processes. Thrombospondin-1 levels have been found 
to be increased in children with SCA in association with both SCI(34) and overt stroke 
(35), although thrombospondin-4 has not previously been studied in this context. 
These findings support the potential use of anticoagulant and antiplatelet agents to 
prevent and treat SCI in SCA. 
 
Pro-inflammatory proteins 
Elevated levels of α
2
-macroglobulin, complement C1s and complement C3 in the SCI 
patients suggest that there is increased inflammation, which is known to predispose 
towards vasculopathy and stroke. As mentioned previously, α
2
-macroglobulin is a 
prothrombotic protease inhibitor, but is also involved in inflammatory states, as a 
carrier for interleukin-6(31). Both complements C1s and C3 are elevated in 
inflammation, and high levels of C3 are a known risk factor for atherosclerosis and 
stroke in the general population(36). Inflammation is known to be an important 
component of pathophysiology in SCA, and the role of anti-inflammatory agents in 
preventing SCIs should be explored further. 
 
Lipoproteins 
Apolipoprotein B-100 is the main component of low density lipoprotein cholesterol 
(LDL-C) and high levels are a well-established risk factor for atherosclerosis. Various 
studies have shown that drugs which reduce LDL-C also reduce the rate of 
cardiovascular events, including ischemic stroke (37), suggesting a possible 
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therapeutic option for children with SCA and ischemic stroke for drugs such as 
statins. We also found that apolipoprotein A-IV levels were higher in the SCI 
population, which is perhaps paradoxical in that it is thought to be protective against 
coronary syndromes (38), although it has not been directly implicated in 
cerebrovascular disease or studied in children. A recent study suggested that higher 
levels were associated with reduced glomerular filtration rates (39), and this could 
be one explanation for the differences in our study. 
 
Other interesting candidates 
Several other interesting candidates were identified, both shedding light on the 
pathophysiology of SCI and with the potential to act as useful biomarkers. 
Gelsolin binds to and remodels actin by both severing and capping the protein; it is 
present in both cytoplasm and plasma. Increased plasma levels have been identified 
as a poor prognostic marker in ischemic stroke (40). Further significant actions in the 
context of SCI include a role in promoting platelet formation and activation (41). In 
our genetic analysis, a genetic variant in the gelsolin gene showed a trend towards 
being associated with SCI. 
 
Retinol binding protein-4 is a lipocalin transporting vitamin A from the liver to other 
tissues, including the brain; plasma levels have been found to be elevated in 
atherosclerosis and also ischemic stroke (42, 43). 
 
Pigment epithelium-derived factor is multifunctional with anti-angiogenic properties, 
secreted by different tissues including adipocytes. It is potentially significant in the 
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development of SCI because of its ability to induce insulin resistance, and 
inflammation and proliferation of muscle cells (44). It is harder to know the 
significance of some other proteins, including the lower levels of immunoglobulin 
chains and platelet basic protein in SCI, although immunodeficiency has been 
associated with primary and recurrent stroke in the general pediatric population(45). 
 
The genetic association analysis did not suggest that any of the protein differences 
seen had a strong genetic basis, although the pathophysiology of SCIs seen in the 
adults used in this part of the study may differ from that in the children used in the 
proteomic part. 
 
Several plausible biomarkers for SCI were identified in the targeted plasma analysis, 
including von Willebrand factor C domain, although none of these reached statistical 
significance when corrected for multiple assays. Similarly, none of the candidate 
proteins identified by proteomics showed a convincing genetic association with SCI 
in a separate cohort of 359 patients with SCA, although the pathophysiology of SCIs 
seen in the adults used in this part of the study may differ from that in the children 
used in the proteomic part. This may also reflect the relatively small size of this 
study, or that the changes seen in proteins of those with SCIs are secondary to other 
pathological events rather than inherited quantitative trait loci. 
 
The strength of our study is that it used an unbiased proteomics approach to identify 
proteins involved in the pathogenesis of SCI, together with a combination of 
targeted plasma analysis and genetic association studies. Our findings suggest that 
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proinflammatory and prothrombotic states contribute to the development of SCI, 
with possible abnormalities in lipoproteins. Previous studies to identify biomarkers 
for SCI in SCD have been summarized by Lance et al (35). They identified nine studies 
measuring a range of different candidates, although no studies used an unbiased 
proteomic approach. 17 potential candidates were identified in this review, again 
with a predominance of factors suggesting coagulation activation and increased 
inflammation (35). None of the identified candidates were the same as our 
candidates, although one study found increased levels of thrombospondin-1 in 
children with SCIs and SCA(34).  
 
Although our study is relatively small, in keeping with proteomic discovery 
approaches, some significant factors have emerged. We confirmed the importance 
of hypertension as a risk factor for SCI, together with support for higher HbF levels 
being protective, suggesting that anti-hypertensives and hydroxyurea may be of 
benefit. The utility of individual biomarkers, such as gelsolin or α-2-antiplasmin, to 
act as clinically useful biomarkers in screening for SCI needs to be confirmed in 
larger, prospective studies. Previous studies have shown increased inflammation and 
coagulation in children with SCD(46, 47), possibly linked to small blood vessel 
disease(48), and our study suggests that this is more marked in children who also 
have SCIs. This relatively prothrombotic and pro-inflammatory state associated with 
SCIs suggests that it may be useful to study anti-inflammatory and antiplatelet 
agents in clinical trials of SCI prevention. On-going clinical trials of antiplatelet 
agents(49), statins(50) and canakinumab are particularly relevant in this context. 
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 Controls Silent cerebral infarction P value 
 n mean s.d. n mean s.d.  
age (years) 32 11.5 3.17 19 12.4 3.82 0.40 
Hb (g/l) 32 83.4 8.45 19 86.1 11.1 0.33 
HbF (%) 32 8.6 5.1 18 6.1 3.6 0.049 
MCH (pg) 32 28.0 4.7 19 28.6 4.0 0.68 
neutrophils 
(x10
9
/l) 
32 4.7 1.6 19 4.4 1.8 0.55 
reticulocytes 
(%) 
27 12.3 3.7 15 12.4 4.7 0.99 
bilirubin 
 
32 40.5 15.5 19 42.9 20.5 0.64 
AST 32 57.5 26.0 19 56.0 19.0 0.84 
Creatinine 
 
32 31.9 9.9 19 36.4 11.8 0.14 
LDH 
 
32 567 135 18 565 148 0.97 
Diastolic bp 
(mmHg) 
26 66.5 6.9 14 66.5 4.9 0.99 
Systolic bp 
(mmHg) 
26 108.6 7.6 14 115 9.6 0.027 
Table 1: Comparison of laboratory and clinical measurements of those with and 
without SCI. P values from t-tests, with significant results shown in bold (P<0.05), not 
corrected for multiple comparisons.  
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Protein Number 
different 
peptides 
Normalized 
concentration 
in controls 
Normalized 
concentration 
in SCI 
Fold 
change 
in SCI 
P value 
α-2-antiplasmin 
 
3 0.635 0.914 1.44 0.004 
Albumin 
 
1 0.505 0.703 1.39 0.005 
α-2-
macroglobulin 
7 0.601 0.832 1.38 0.01 
Apolipoprotein A-
IV 
7 0.28 0.421 1.50 0.0002 
Apolipoprotein B-
100 
1 0.303 0.428 1.41 0.014 
Complement C1s 
 
1 0.42 0.565 1.34 0.014 
Complement C3 
 
2 0.414 0.561 1.35 0.004 
Fibrinogen 
γ chain 
1 0.936 1.25 1.33 0.01 
Gelsolin 
 
10 0.411 0.577 1.40 0.00006 
Inter-α−trypsin 
inhibitor heavy 
chain-1 
2 0.833 1.14 1.36 0.002 
Pigment 
epithelium-
derived factor 
1 1.14 1.5 1.32 0.006 
Retinol-binding 
protein 4 
3 0.465 0.625 1.34 0.002 
Thrombospondin-
4 
 
2 0.577 0.763 1.32 0.001 
 
Table 2: List of all peptides and proteins present at significantly increased 
concentrations (>1.3 fold) in children with SCIs compared to controls. Where more 
than one peptide was identified, the most significant difference is given. 
Concentrations are normalized against standard controls.  
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Protein Number 
different 
peptides 
Normalized 
concentration 
in controls 
Normalized 
concentration 
in SCI 
Fold 
change in 
SCI 
P value 
Ig alpha-1 
chain 
1 0.757 0.541 0.71 0.021 
Ig gamma-
1 chain 
35 1.74 1.09 0.63 0.018 
Ig gamma- 
3 chain 
1 1.08 0.821 0.76 0.035 
Platelet 
basic 
protein 
4 1.865 1.27 0.68 0.015 
 
Table 3: List of all peptides and proteins present at significantly decreased 
concentrations (>0.77 fold) in children with SCIs compared to controls. Where more 
than one peptide was identified, the most significant difference is given. 
Concentrations are normalized against standard controls. 
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Protein Gene Symbol Chromosome 
Number of SNPs 
analysed 
P value of most 
significant  
genetic variant 
alpha-2-
macroglobulin A2M 9 431 0.0140 
albumin ALB 4 89 0.0016 
apoliprotein B-
100 APOB 2 180 0.0587 
complementC1s C1S 12 360 0.0016 
complement C3 C3 19 449 0.0257 
Fibrinogen 
gamma chain FGG 4 23 0.0258 
gelsolin GSN 9 607 0.0003 
Ig alpha-1 chain IGHA1 14 25 0.2699 
Ig gamma-1 
chain IGHG1 14 43 0.0609 
Ig gamma-3 
chain IGHG3 14 26 0.0488 
inter-alpha-
trypsin inhibitor 
heavy chain ITIH1 3 75 0.0180 
pigment 
epithelium-
derived factor PEDF/SERPINF1 17 117 0.0495 
platelet basic 
protein PPBP 4 4 0.4393 
retinol-binding 
protein 4 RBP4 10 99 0.0040 
alpha-2-
antiplasmin SERPINF2 17 70 0.0233 
thrombospondin 
4 THBS4 5 387 0.0207 
 
Table 4: Association of candidate genes for SCI identified in the proteomic part of the 
study. The most significant genetic variants are shown. None of the variants were 
significant after adjustment for multiple comparisons. 
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 Unadjusted P value Corrected P value 
Von Willebrand factor C domain 
containing Protein 2 
0.03 0.62 
Smooth muscle-associated 
protein 2 
0.02 0.62 
ADAM metalloproteinase 
domain 22 
0.04 0.62 
ADAM metalloproteinase 
domain 23 
0.04 0.62 
Scavenger receptor class A 
member 5 
0.03 0.62 
TNF receptor superfamily 
member 12A 
0.02 0.62 
Bone morphogenetic protein 4 
 
0.03 0.62 
 
Table 5: Known biomarkers of neurological disease showing significant differences 
between SCI and control populations, although none of these maintain significance 
when correcting for multiple tests. 
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Figure Legend 
Figure 1: Diagram showing the flow of patients through the study. 
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Supplementary	Materials	
Brain	MRI	and	Neurological	Examination	
Many	of	the	eligible	children	for	this	study	had	previously	had	brain	MRI	for	routine	
clinical	or	research	purposes.	MRI	results	were	considered	eligible	for	entry	into	this	
study	if	performed	in	the	12	months	preceding	the	date	of	consent.		Children	known	
to	have	SCIs	based	on	previous	MRIs	were	selectively	recruited	to	the	study.	Children	
without	an	MRI	in	the	last	12	months	had	an	MRI	scan	performed	specifically	as	part	
of	this	study	within	4	weeks	of	blood	sampling,	and	were	assigned	to	either	the	
control	or	SCI	group.	A	pediatric	neuroradiologist	with	experience	of	interpreting	
MRIs	in	children	with	sickle	cell	disease	reported	all	scans.	SCI	was	defined	as	a	signal	
abnormality	visible	on	axial	and	coronal	planes	on	the	T2-weighted	images,	which	is	
at	least	3mm	in	one	dimension,	without	a	history	of	overt	stroke	or	a	neurological	
deficit	corresponding	to	the	MRI	lesion.	
Proteomic	Methods	
TMT®s	(Proteome	Sciences	plc)	are	a	set	of	isobaric	mass	tags	for	labeling	proteins	
and	peptides	at	amine	functions	and	subsequent	mixing	of	up	to	ten	different	
protein	samples.	During	MS/MS,	each	set	of	tags	gives	rise	to	different	reporter	ions	
with	specific	molecular	masses	thus	allowing	them	to	share	the	same	chemical	
structure	but	have	different	molecular	weights	dependent	on	the	different	number	
of	heavy	isotopes	contained.	Peptides	labelled	with	different	TMTs	show	identical	
chromatographic	retention	times	as	well	as	identical	ionization	and	fragmentation	
behavior	of	tags	and	tagged	species.	
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The	proteins	were	initially	digested	into	peptides	using	trypsin,	and	TMT	labeling	
then	performed.	Off	gel	fractionation	was	then	used	to	separate	the	peptides	prior	
to	LC-MS/MS.	Protein	discovery	study	was	performed	in	a	reference-controlled	
manner	and	this	approach	generated	considerable	coverageof	the	plasma	
proteome(45).	
		
Mass	spectral	data	were	acquired	using	an	Orbitrap	Velos	mass	spectrometer	
(Thermo	Scientific).	Compilation	and	validation	of	the	peptide	and	protein	
assignments	were	carried	out	using	Proteome	Discoverer	v1.3	(Thermo)	and	Scaffold	
v2.6	(Proteome	Software	Inc)	mass	spectrometry	software.	Proteins	were	quantified	
based	on	the	intensities	of	the	reporter	ions	released	from	the	TMT	tags	during	
MS/MS	of	peptides.	The	use	of	the	TMT10plex	reagents	enabled	the	simultaneous	
analysis	of	five	samples	alongside	an	overall	study	reference	comprising	of	a	pool	of	
all	subjects.	The	proteomics	study	comprised	5	separate	TMT10plex	experiments,	
each	with	10	samples	and	a	reference	channel	for	normalization	purposes.	
	
Data	were	exported	for	each	TMT	set	into	an	Excel	file,	and	duplicate	peptides	were	
removed.	The	data	were	filtered	so	that	only	peptides	identified	in	all	10	sample	
channels	were	analysed	further.	The	data	were	normalized	and	merged	against	the	
peptide	sequence	using	R	software.	The	merged	data	were	further	filtered	such	that	
only	peptides	present	in	all	patient	samples	were	studied.	Relative	amounts	of	each	
peptide	were	compared	between	the	SCI	and	control	groups,	and	P	values	
calculated,	for	those	samples	with	>1.3	fold	differences.	
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Neurological	biomarkers	included	multiplexed	proximity	extension	assay	
Plasma	samples,	anticoagulated	with	EDTA,	were	frozen	at	-80oC	within	6	hours	of	
venesection,	and	transported	as	one	batch	to	Olink	Proteomics	in	Sweden	
(www.olink.com/proseek-multiplex)	on	dry	ice	for	analysis	using	their	Proseek	
Multiplex	Neurology	I	panel,	which	includes	the	following	markers:	
ADP-ribosyl	cyclase/cyclic	ADP-ribose	hydrolase	1	(CD38)	
Alpha-2-macroglobulin	receptor-associated	protein	(Alpha-2-MRAP)	
BDNF/NT-3	growth	factors	receptor	(NTRK2)	
Beta-nerve	growth	factor	(Beta-NGF)	
Bone	morphogenetic	protein	4	(BMP-4)	
Brain-derived	neurotrophic	factor	(BDNF)	
Brevican	core	protein	(BCAN)	
Brorin	(VWC2)	
C-type	lectin	domain	family	1	member	B	(CLEC1B)	
C-type	lectin	domain	family	10	member	A	(CLEC10A)	
Cadherin-3	(CDH3)	
Cadherin-6	(CDH6)	
Carboxypeptidase	A2	(CPA2)	
Carboxypeptidase	M	(CPM)	
Cathepsin	S	(CTSS)	
Cell	adhesion	molecule	3	(CADM3)	
Cell	surface	glycoprotein	CD200	receptor	1	(CD200R1)	
CMRF35-like	molecule	1	(CLM-1)	
CMRF35-like	molecule	6	(CLM-6)	
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Contactin-5	(CNTN5)	
Cytotoxic	and	regulatory	T-cell	molecule	(CRTAM)	
Dickkopf-related	protein	4	(Dkk-4)	
Dipeptidyl	peptidase	1	(CTSC)	
Disintegrin	and	metalloproteinase	domain-containing	protein	22	(ADAM	22)	
Disintegrin	and	metalloproteinase	domain-containing	protein	23	(ADAM	23)	
Draxin	(DRAXIN)	
Ephrin	type-B	receptor	6	(EPHB6)	
Ephrin-A4	(EFNA4)	
Epithelial	discoidin	domain-containing	receptor	1	(DDR1)	
Ezrin	(EZR)	
Fc	receptor-like	protein	2	(FcRL2)	
Galectin-8	(gal-8)	
GDNF	family	receptor	alpha-1	(GFR-alpha-1)	
GDNF	family	receptor	alpha-3	(GDNFR-alpha-3)	
Glial	cell	line-derived	neurotrophic	factor	(GDNF)	
Glypican-5	(GCP5)	
Granulocyte	Colony-Stimulating	Factor	(G-CSF)	
Granulocyte-macrophage	colony-stimulating	factor	receptor	subunit	alpha	(GM-CSF-
R-alpha)	
Granzyme	A	(GZMA)	
Growth/differentiation	factor	8	(GDF-8)	
Hydroxyacylglutathione	hydrolase,	mitochondrial	(HAGH)	
Interleukin-12	subunit	beta,	Interleukin-12	subunit	alpha	(IL-12B,	IL-12A)	
	 5	
Interleukin-5	receptor	subunit	alpha	(IL-5R-alpha)	
Junctional	adhesion	molecule	B	(JAM-B)	
Kynureninase	(KYNU)	
Latexin	(LXN)	
Layilin	(LAYN)	
Leucine-rich	repeat	transmembrane	protein	FLRT2	(FLRT2)	
Leukocyte-associated	immunoglobulin-like	receptor	2	(LAIR-2)	
Linker	for	activation	of	T-cells	family	member	1	(LAT)	
Lysosome	membrane	protein	2	(SCARB2)	
Macrophage	scavenger	receptor	types	I	and	II	(MSR1)	
MAM	domain-containing	glycosylphosphatidylinositol	anchor	protein	1	(MDGA1)	
Matrilin-3	(MATN3)	
Mesencephalic	astrocyte-derived	neurotrophic	factor	(MANF)	
N-acylethanolamine-hydrolyzing	acid	amidase	(NAAA)	
Neprilysin	(NEP)	
Netrin	receptor	UNC5C	(UNC5C)	
Neuroblastoma	suppressor	of	tumorigenicity	1	(NBL1)	
Neurocan	core	protein	(NCAN)	
Neuronal	cell	adhesion	molecule	(Nr-CAM)	
Neuropilin-2	(NRP2)	
Neutral	ceramidase	(N-CDase)	
Nicotinamide/nicotinic	acid	mononucleotide	adenylyltransferase	1	(NMNAT1)	
NKG2D	ligand	2	(N2DL-2)	
NT-3	growth	factor	receptor	(NTRK3)	
	 6	
OX-2	membrane	glycoprotein	(CD200)	
Platelet-derived	growth	factor	receptor	alpha	(PDGF-R-alpha)	
Plexin-B1	(PLXNB1)	
Plexin-B3	(PLXNB3)	
Poliovirus	receptor	(PVR)	
Protogenin	(PRTG)	
R-spondin-1	(RSPO1)	
Repulsive	guidance	molecule	A	(RGMA)	
RGM	domain	family	member	B	(RGMB)	
Roundabout	homolog	2	(ROBO2)	
Scavenger	receptor	class	A	member	5	(SCARA5)	
Scavenger	receptor	class	F	member	2	(SCARF2)	
Secreted	frizzled-related	protein	3	(sFRP-3)	
Serine/threonine-protein	kinase	receptor	R3	(SKR3)	
Sialic	acid-binding	Ig-like	lectin	9	(Siglec-9)	
Sialoadhesin	(SIGLEC1)	
SPARC-related	modular	calcium-binding	protein	2	(SMOC2)	
Sphingomyelin	phosphodiesterase	(SMPD1)	
Tenascin-R	(TN-R)	
Testican-1	(SPOCK1)	
Thy-1	membrane	glycoprotein	(THY	1)	
Transmembrane	protease	serine	5	(TMPRSS5)	
Tumor	necrosis	factor	receptor	superfamily	member	12A	(TNFRSF12A)	
Tumor	necrosis	factor	receptor	superfamily	member	21	(TNFRSF21)	
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Tumor	necrosis	factor	receptor	superfamily	member	27	(EDA2R)	
WAP,	Kazal,	immunoglobulin,	Kunitz	and	NTR	domain-containing	protein	1	
(WFIKKN1)	
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Genetic	Association	study	
The	adult	cohort	used	in	this	part	of	the	study	had	previously	had	genome-wide	
genotyping	array	performed	using	Illumina’s	Infinium	MEGA	chip	(Multi	Ethnic	
Genotyping	Array).	Genotyping	data	were	quality	controlled	and	imputed	to	1000	
Genomes	phase	3	reference	set	using	the	online	Michigan	server.	359	individuals	
with	SCD	had	genotyping	as	well	as	MRI	data	available,	and	were	classified	as	having	
SCI	or	not;	patients	with	large	vessel	vasculopathy,	overt	stroke	or	no	brain	MRI	
were	excluded.	We	performed	a	mixed	modeling	analysis	incorporating	a	genetic	
relatedness	matrix	to	take	account	of	relatedness	(including	population	
stratification),	sex,	age	at	MRI,	and	sickle	genotype	as	fixed	covariates.	Each	gene	
analysed	contained	multiple	genetic	variants;	we	corrected	for	multiple	testing	after	
quantifying	the	linkage	disequilibrium	within	each	region	and	used	this	to	calculate	
appropriate	significance	levels	for	that	region		
